International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE
← catalyst calendarNCT07191548 · readout ≤ 559 d
Sponsored by Angiodynamics, Inc. (industry) · ANGO — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Feb 2026 | estimated | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver
- Liver Ablation
- Liver Cancer, Adult
Intervention
- Device: Irreversible Electroporation — also filed as nanoknife
Primary outcome
what the primary-completion date above is the date OFTarget Tumour Eradication
measured 6 months
Permalink · ANGO's whole pipeline · Catalyst calendar · Every registered study · What changed